A statement released earlier today by Societe Generale about Bayer (ETR:BAYN) bumps the target price to 105.00EUR
- Updated: September 16, 2016
Only yesterday Bayer (ETR:BAYN) traded 0.00% even at 91.44EUR. BAYN’s 50-day moving average is 0.04EUR and its 200-day average is 0.03EUR. The last stock close is up 1.82% from the 200-day average, compared to the Standard & Poor’s 500 Index which has decreased -0.01% over the same time. Volume of trade was was down over the average, with 0 shares of BAYN changing hands under the typical 211 shares..
In an issued report on 9/16/2016 Societe Generale bumped up the target price of Bayer (ETR:BAYN) from 0EUR to 105EUR reporting a possible upsideof 0.15%.
On 8/29/2016, Citigroup Corp. released a statement for Bayer(ETR:BAYN) raised the target price from 0.00EUR to 120.00EUR that suggested an upside of 0.24%.
See Graph Below:
Bayer has a 52 week low of 0.03EUR and a 52 week high of 0.04EUR and has a market cap of 0.0 EUR.
More About Bayer (ETR:BAYN)
Bayer AG is a life science company. The Company’s segments are Pharmaceuticals, Consumer Health, Crop Science, Animal Health and Covestro. The Pharmaceuticals segment is engaged in the development of prescription pharmaceuticals; contraceptives, and medical products, such as injection systems and contrast agents for diagnostic procedures. The Consumer Health segment is engaged in the development of over-the-counter medications, dermatology products and nutritional supplements. The Crop Science segment is engaged in the development of product portfolio in the areas of seeds and plant traits, crop protection, home and garden, the green industry and nonagricultural pest control. The Animal Health segment is engaged in the development of veterinary medicines and animal grooming products. Covestro is engaged in the development of raw materials for polyurethanes; polycarbonate resins and sheets; raw materials for coatings, and adhesives and sealants; and selected chemical intermediates.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.